A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site - Investing.com
Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site Investing.com
Earnings call transcript: Lonza Group Q3 2025 sees strong CDMO growth - Investing.com
Earnings call transcript: Lonza Group Q3 2025 sees strong CDMO growth Investing.com
Lonza's recently purchased Calif. biologics site plays key role in sales rebound - Fierce Pharma
Lonza's recently purchased Calif. biologics site plays key role in sales rebound Fierce Pharma
Lonza Reports Strong Q3 2025 and Confirms Full-Year Outlook - TipRanks
Lonza Reports Strong Q3 2025 and Confirms Full-Year Outlook TipRanks
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses - TradingView
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses TradingView
Lonza confirms outlook as it expects more contracts in coming months - Reuters
Lonza confirms outlook as it expects more contracts in coming months Reuters
CPHI 2025: Lonza Capsugel spotlights delivery tech and sustainability in nutraceuticals - nutritioninsight.com
CPHI 2025: Lonza Capsugel spotlights delivery tech and sustainability in nutraceuticals nutritioninsight.com
GBCC and Lonza partner for apprenticeship program - NH Business Review
GBCC and Lonza partner for apprenticeship program NH Business Review
Lonza expands its GMP solutions for cell and gene therapy - SelectScience
Lonza expands its GMP solutions for cell and gene therapy SelectScience
Lonza Capsugel launches organic, vegan capsule line - SupplySide Supplement Journal
Lonza Capsugel launches organic, vegan capsule line SupplySide Supplement Journal
Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH) - the-scientist.com
Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH) the-scientist.com
Is Now An Opportune Moment To Examine Lonza Group AG (VTX:LONN)? - Yahoo Finance
Is Now An Opportune Moment To Examine Lonza Group AG (VTX:LONN)? Yahoo Finance
Lonza Group: Growth, Signs Of Overvaluation, And A New Management Cause Uncertainty - Seeking Alpha
Lonza Group: Growth, Signs Of Overvaluation, And A New Management Cause Uncertainty Seeking Alpha
Lonza Completes New Drug Product Filling Line in Stein, Switzerland - Contract Pharma
Lonza Completes New Drug Product Filling Line in Stein, Switzerland Contract Pharma
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk...
Lonza Expands Cell and Gene Therapy Portfolio - Contract Pharma
Lonza Expands Cell and Gene Therapy Portfolio Contract Pharma
Lonza Announces Innovation Day at SupplySide Global - WholeFoods Magazine
Lonza Announces Innovation Day at SupplySide Global WholeFoods Magazine
Lonza announces new board nominee - The Vacaville Reporter
Lonza announces new board nominee The Vacaville Reporter
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page